The study will compare gene expression differences between blistered and non-blistered skin from individuals with EBS, as well as normal skin from non-EBS subjects. State of the art computational analysis will be performed to help identify new drugs that might help EBS wound healing and reduce pain. Researchers will focus on drugs that have already been approved for treatment of other dermatologic or non-dermatologic diseases, and therefore be repurposed for treatment of EBS. Drug development is a very expensive process taking decades for execution. Drug repurposing on the other hand, significantly reduces the cost and shortens the amount of time that is needed to bring effective treatments to clinical use. To date, there is no specific treatment targeting the physiology and immunologic response in EB patients during wound healing. Market availability of repurposed medications will provide EBS patients rapid access to treatments, thus improving their quality of life.